PacSci EMC Competes on National Stage as NASA iTech Innovation Competition Finalist
PacSci EMC recently participated as a finalist in NASA’s second iTech Forum, competing to have their innovative idea selected as one of the top 10 in a yearlong initiative to find and foster innovative solutions with the potential to benefit NASA and the nation in the future.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720006386/en/
Douglas Terrier, Acting Chief Technologist, NASA presents Peter Current, Steve Nelson, and Bret Omsberg with a certificate recognizing “PacSci EMC as a top 10 finalist of NASA iTech’s Cycle 2 on July 13, 2017.” Photo Credit: NASA
The teams competed against entrepreneurs presenting their proposed solutions to tough technology challenges to judges consisting of NASA’s chief technologists, space industry leaders and potential investors. Hosted by the National Institute of Aerospace in Hampton, Virginia, from July 10-13, the forum brought together finalists from across the U.S. to compete and showcase their innovations.
"NASA iTech is unique in that it reveals groundbreaking technology solutions and provides a catalyst for industry investors, government agencies and small businesses to collaborate with the innovators to mature their technologies for both space and commercial applications,” said Kira Blackwell, Innovation program executive in the Office of the Chief Technologist at NASA Headquarters in Washington.
The cutting edge technologies presented by the finalists may solve some of the most challenging problems on Earth and have the potential to solve some of NASA’s deep space exploration challenges. The technology focus areas for NASA iTech Cycle 2 were: Autonomy, Big Data - Data Mining and Machine Learning, Medical Systems and Operations and Radiation Protection and Mitigation. An additional category, X-Factor Innovations: Solutions for Unspecified Future Challenges, was added for Cycle 2 to allow for groundbreaking ideas or technology that may not align precisely with another specific focus area, but could still make a significant impact on future exploration efforts.
PacSci EMC submitted its Modular Architecture Propulsion System (MAPS™) under “X-Factor Innovations: Solutions for Unspecified Future Challenges.” MAPS takes the equivalent energy found in a tank of toxic liquid fuel and quantizes it into an array of sealed, solid propellant rocket motors safely commanded by a low power, Smart Energetics Architecture (SEA™) bus. MAPS “plug and play” simplicity eliminates tanks, valves, plumbing, and large power supplies while greatly enhancing customer workflows. MAPS is fully operational in 5 milliseconds with a 10+ year on-orbit life.
“The quality of the top ten finalists was eye-opening and judging among the top entrants was extremely close,” said Blackwell. “Our goal is for iTech to provide a catalyst for industry investors, government agencies and small businesses to collaborate with the best innovators to mature their technologies for both space and commercial applications and PacSci EMC along with our other our top ten finalists have a bright future ahead.”
For more information about NASA iTech, visit: http://www.NASAiTech.com
ABOUT PACIFIC SCIENTIFIC ENERGETIC MATERIALS COMPANY LLC (PacSci EMC):
PacSci EMC has a deep history serving both manned and unmanned space exploration and satellite missions. Our products are used in all phases of space flight beginning with ground-based operations through lift-off/boost, solid rocket booster jettison, payload fairing separation, booster separation, second stage flight, payload separation and flight termination. We have put this expertise to work creating MAPS™, an innovative and highly reliable, non-pressurized, solid propellant, “plug and play” propulsion system for use on CubeSats and SmallSats. For over 65 years, our customers have relied on our expertise and dedication to safety and quality. Discover more: https://www.psemc.com/.
Pacific Scientific Energetic Materials Company (PacSci EMC)
Steve Nelson, 661-917-2947
National Institute of Aerospace, Hampton, Va.
Timothy Allen, 615-955-2859
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58 | Pressemelding
Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs